Phase II study of CC-5013 [lenalidomide] in patients with advanced renal cell carcinoma (RCC)

Trial Profile

Phase II study of CC-5013 [lenalidomide] in patients with advanced renal cell carcinoma (RCC)

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 12 Feb 2009 Additional lead investigator identified as reported by ClinicalTrials.gov, last updated 12-2-2009.
    • 01 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top